

*Curriculum Vitae – John Posner*  
**John Posner BSc PhD MBBS FRCP FFPM**

**PUBLICATIONS**

**Books and Chapters**

Posner J

Pain models in healthy volunteers.

The Role of Clinical Measurement in Evaluation of New Drugs.

Publ. Woolf Edinburgh. Ed. Nimmo WS & Tucker G 1991; Chapter 8: 73-90

Posner J

The Textbook of Pharmaceutical Medicine. Chapter 4: Exploratory Development.

Publ. Ed. Griffin, O’Grady and Wells, 4<sup>th</sup> edition 2002 and previous editions.

Posner J, Rolan PE

The Textbook of Pharmaceutical Medicine. Chapter 5: Clinical Pharmacokinetics

Publ. Ed. Griffin, O’Grady and Wells, 3rd edition 1998 and previous editions.

Cohen AF, Posner J (Editors)

A Guide to Clinical Research.

Publ. Kluwer Academic Publishers Inc. 2<sup>nd</sup> edition 2000 (1<sup>st</sup> edition 1995)

**Editorials and Letters**

Cohen AF, Posner J

Effects of 2 antihistamine drugs on actual driving performance.

Br Med J 1984; 288: 935.

Posner J

Clinical pharmacology - mutual benefits from greater cooperation between academia and the pharmaceutical industry.

Br J Clin Pharmac 1991; 32: 531-533.

Harry J, Baber N and Posner J

HIV screening in healthy volunteers.

Br J Clin Pharmac 1995; 39: 213.

**Abstracts**

Author of more than 50 peer-reviewed abstracts of oral and poster presentations mostly published in the British Journal of Clinical Pharmacology and numerous other posters presented at international conferences and symposia

## *Curriculum Vitae – John Posner*

### **Refereed Papers**

Bennett A, Posner J

Studies on prostaglandin antagonists.

Br J Pharmac 1971; 42: 584-594.

Posner J

Prostaglandin E<sub>2</sub> and the bovine sphincter pupillae.

Br J Pharmac 1973; 49: 415-427.

Larson E, Nicholson C, Loewi G, Posner J, Tyrrell DAJ

Arthritis after meningococcal meningitis.

Br Med J 1977; 1: 618

Berginer V, Posner J, Kahana E

Multiple Sclerosis in Israeli Bedouin.

Israel J Med Sci 1982; 18: 249-252.

Posner J, Ilya R, Wanderman K, Weitzmann S

Systolic Time Intervals in Diabetes.

Diabetologia 1983; 24: 249-252.

Weinhouse E, Kaplansky Y, Posner J

Comparison of digoxin-induced cardiac toxicity in resistant and sensitive species.

J Pharm Pharmacol 1983; 35: 580-583.

Posner J, Sobel RJ, Glick S

Effects of amiodarone on thyroid hormone economy.

Israel J Med Sci 1984; 20: 113-117.

Posner J

A modified submaximal effort tourniquet test for evaluation of analgesics.

Pain 1984; 19: 143-151.

Posner J, Bye A, Jeal S, Peck AW, Whiteman PD

Alcohol and pharmacokinetics of bupropion in healthy volunteers.

Europ J Clin Pharmacol 1984; 26: 627-630.

Cohen AF, Posner J, Ashby L, Smith R, Peck AW

A comparison of methods of assessing the sedative effects of diphenhydramine on skills related to car driving.

Europ J Clin Pharmacol 1984; 27: 471-475.

## *Curriculum Vitae – John Posner*

Whiteman PD, Bye A, Fowle ASE, Jeal S, Land G, Posner J

Tolerance and pharmacokinetics of an acyclovir analogue A515U in man.

Europ J Clin Pharmacol 1984; 27: 471-475.

Posner J, Telekes A, Crowley D, Phillipson R, Peck AW

Effects of an opiate on cold-induced pain and the CNS in healthy volunteers.

Pain 1985; 23: 73-82.

Posner J, Bye A, Dean K, Peck AW, Whiteman PD

The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses.

Europ J Clin Pharmacol 1985; 29: 97-103.

Posner J, Burke CA

The effects of naloxone on opiate and placebo analgesia in healthy volunteers.

Psychopharmacol 1985; 87: 468-473.

Findlay JWA, Fowle ASE, Butz RF, Jones EC, Weatherley BC, Welch RM, Posner J

Comparative disposition of codeine and pholcodine in man after single oral doses.

Br J Clin Pharmacol 1986; 22: 61-71.

Posner J, Danhof M, Theunissen MWE, Breimer DD, Whiteman PD

The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

Br J Clin Pharmacol 1987; 24: 51-55.

Posner J, Dean K, Jeal S, Moody SG, Peck AW, Rutter G, Telekes A.

A preliminary study of the pharmacodynamics and pharmacokinetics of a novel enkephalin analogue [Tyr.D.Arg-Gly-Phe(4NO<sub>2</sub>).Pro.NH<sub>2</sub>(BW443C)] in healthy volunteers.

Europ J Clin Pharmacol 1988; 34: 67-71.

Posner J, Cohen AF, Land G, Winton C, Peck AW

The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinemia (Gilbert's Syndrome).

Br J Clin Pharmacol 1989; 28: 117-120.

Rolan PE, Adams J, Posner J

Histamine bronchial challenge in volunteers.

J Int Med Res 1989; 17: Suppl 2: 35-39B.

Posner J, Moody SG, Peck AW, Rutter D, Telekes A

Analgesic, central, cardiovascular and endocrine effects of the enkephalin analogue Tyr-D.Arg-Cly-Phe(4NO<sub>2</sub>)-Pro-NH<sub>2</sub>(443C81) in healthy volunteers

Europ J Clin Pharmacol 1990; 38: 213-218.

## *Curriculum Vitae – John Posner*

Rolan PE, Phillips S, Adams J, Posner J

The onset of effect of the H<sub>1</sub>-antagonist acrivastine (“Semprex”) assessed by histamine bronchial challenge in volunteers.

Europ J Clin Pharmacol 1990; 39: 311-313.

Cohen AF, Harkin N, Posner J

The cardiovascular effects of a novel enkephalin analogue, 443C81, in man.

J Cardiovas Pharmacol 1990; 16: 455-460.

Posner J, Holdich T, Crome P

Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers.

J Pharmaceut Med 1991; 1: 121-128.

Chowdry NB, Gray SJ, Posner J, Fuller RW

The effect of 443C81, a opioid receptor agonist, on the response to inhaled capsaicin in healthy volunteers.

Br J Clin Pharmacol 1991; 32: 633-636.

Gray SJ, Parker JE, Giles H, Bolofo M, Phillips S, Posner J

The effects of a partial PGD<sub>2</sub> agonist, 192C, on platelet aggregation and the cardiovascular system in healthy volunteers.

Br J Clin Pharmacol 1992; 34: 344-351.

Phillips SC, Rolan PE, Posner J, Malpern S, Wijayawardhana P, Crome P.

Greater ease of swallowing of a new film coated 800 mg dispersible acyclovir (Zovirax) tablet compared to the standard 800 mg tablet in healthy elderly volunteers.

J Pharm Med 1992; 2: 259-262.

Rolan PE, Parker JE, Gray SJ, Weatherley BC, Ingram J, Leavens W, Wootton R, Posner J.

The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80:4)[2-formyl-3-hydroxyphenoxymethyl], a potential anti-sickling agent, following oral administration to healthy subjects.

Br J Clin Pharmacol 1993; 35:419-425.

Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J

Examination of some factors responsible for a food-induced increase in the absorption of atovaquone.

Br J Clin Pharmacol 1994; 37: 13-20.

Peck RW, Wootton R, Lee DR, Jackson SHD, Posner J

The bioavailability and disposition of 1-β-D-arabinofuranosyl)-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent.

Br J Clin Pharmacol 1995; 39: 143-149.

Peck RW, Weatherley BC, Wootton R, Crome P, Holdich TA, Posner J

Pharmacokinetics and tolerability of single oral doses of 882C87, a potent new anti-varicella zoster virus agent, in healthy volunteers.

Antimicrobial Agents and Chemotherapy 1995; 39: 20-27.

## *Curriculum Vitae – John Posner*

Rolan PE, Mercer A, Wootton R, Posner J

Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.  
Br J Clin Pharmac 1995; 39: 375-380.

Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.  
Antimicrobial agents and Chemotherapy 1995; 39: 2759-2764.

Peck R, Wiggs R, Posner J

The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an AcylCoA:Cholesterol Acyl Transferase (ACAT) inhibitor with low bioavailability in healthy volunteers.  
Europ J Clin Pharmacol. 1995; 49: 243-249.

Mercer A, Hussein Z, Lamb R, Hobbiger S, Posner J

The pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers.  
Ann NY Acad Sci. 1995; 765: 324-327.

Peck RW, Wiggs R, Callaghan J, Wootton R, Crome P, Fraser I, Frick L, Posner J

Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the antiviral zoster virus agent, netivudine.  
Clin Pharmacol Therap 1996; 59: 22-31.

Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan PE

The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers.  
Br J Clin Pharmac 1996; 41:141-148.

De Bony F, Bidault R, Peck R, Posner J

Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid.  
J Antimicrob Chemotherap 1996; 37: 383-387.

Fillastre JP, Godin M, Legallicier B, Chretien P, Bidault R, Gilotin C, Wootton R, Posner J, Peck RW

Pharmacokinetics of netivudine, a potent antiviral zoster virus drug, in patients with renal impairment.  
J Antimicrob Chemotherap 1996; 37: 965-974.

Le Roy F., Godin M, Legallicier B, Fillastre JP, Bidault R, Posner J, Peck RW

Pharmacokinetics of netivudine in haemodialysis patients.  
J Antimicrob Chemotherap 1996; 38:913-915.

Hussein Z, Fraser IJ, Lees KR, Muir KW, Lunnon MW, Hobbiger SF, Posner J

Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions.

### *Curriculum Vitae – John Posner*

Br J Clin Pharmac 1996; 41: 505-513.

Arya R, Rolan PE, Wootton R, Posner J, Bellingham AJ

Tucarecol increases oxygen affinity and reduces hemolysis in subjects with sickle cell anaemia.

Br J Haematol 1996; 93: 817-821.

Davis JD, Dixon R, Khan AZ, Toon S, Rolan PE, Posner J

Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers.

Br J Clin Pharmac 1996; 42: 246-248.

Dixon R, Pozniak AL, Watt HM, Rolan P, Posner J

Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients.

Antimicrob Agents Chemother 1996; 40:556-560.

Wootton R, Soul-Lawton J, Rolan PE, Fook Sheung CTC, Cooper JDH, Posner J

Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers.

Br J Clin Pharmac 1997; 43:23-27

Hussein Z, Posner J

Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: a retrospective analysis of routine monitoring data.

Br J Clin Pharmac 1997; 43:457-465

Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW

The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers

Br J Clin Pharmac 1997; 43:273-281

Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrot J, Chittick G, Posner J, Rolan PE, Peck RW

The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90)

Br J Clin Pharmac 1997; 43:579-587.

Dixon RM, Meire HB, Posner J, Rolan PE

Evaluation of non-invasive techniques to assess vasoconstriction in healthy volunteers using methoxamine as a probe drug.

Cephalalgia 1997; 17:639-646.

Rolan PE, Mercer AJ, Tate E, Benjamin I, Posner J

Disposition of atovaquone in humans.

Antimicrob Agents Chemother 1997, 41:1319-1321.

## *Curriculum Vitae – John Posner*

Seaber EJ, Ridout G, Layton G, Posner J, Peck RW

The novel anti-migraine compound zolmitriptan (Zomig 311C90) has not clinically significant interactions with paracetamol or metoclopramide.

Eur J Clin Pharmacol 1997, 53:229-234.

Peck RW, Seaber EJ, Dixon R, Gillotin CG, Weatherley BC, Layton G, Posner J

The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).

Br J Clin Pharmacol 1997, 44:595-599.

Dixon, RM, Meire HB, Evans DH, Watt H, On N, Posner J, Rolan PE

Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with ergotamine in healthy volunteers.

Cephalgia 1997, 17:639-646.

Peck RW, Seaber EJ, Dixon RM, Layton GR, Weatherley BC, Jackson SHD, Rolan PE, Posner J

The pharmacodynamics and pharmacokinetics of the 5HT<sub>1B/D</sub> - agonist zolmitriptan in healthy young and elderly men and women.

Clin Pharmacol Ther 1998; 63:342-353.

Soul-Lawton JH, Weatherley BC, Posner J, Layton G, Peck RW

Lack of interaction between valaciclovir, the L-valyl ester of aciclovir and digoxin.

Br J Clin Pharmacol 1998; 45:87-89.

Mercer AJ, Lamb RJ, Rolan, PE, Gibbens M, Posner J

Lack of an effect of zolmitriptan (Zomig, 311C90), on psychometric task performance: results of a placebo controlled study in healthy volunteers.

Psychopharmacology 1998, 140:398-404.

Peck RW, Wooton R, Wiggs R, Layton G, Posner J

Effect of food and gender on the pharmacokinetics of tucaresol in healthy volunteers

Br J Clin Pharmacol 1998, 46:83-86.

Klamt JG, Posner J

Effects of lamotrigine on pain-induced chemo-somatosensory evoked potentials

Anaesthesia 1999, 54:774-777.

De Bony F, Tod M, Bidault R, On NT, Posner J, Rolan P

Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother. 2002, 46:458-63.

Calder N, Boyce M, Posner J, Sciberras D

Clinical pharmacology studies in UK Phase I units: an AHPPI survey 1999-2000

Br J Clin Pharmacol 2004; 57:76-79.